Category Archives: Cardiovascular Pharmacology

SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated ( CYTK) today announced three Late-Breaking Science presentations at Heart Failure 2022, an International Congress of the European Society of Cardiology taking place online and in Madrid, Spain from May 21, 2022 May 24, 2022. The presentations will include interim data from the open-label extension study of aficamten, REDWOOD-HCM OLE (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM) and two additional analyses from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), one on the effect of treatment with omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF) and low blood pressure, and the other on the impact of tricuspid regurgitation on clinical outcomes in patients with HFrEF. Continue reading →

South Koreas fight against smoking has had some success. In 1998, when the first nationwide survey of smoking prevalence was conducted in the country, more than 35 out of every 100 Korean adults were smokers. Now, it is just about 19. Continue reading →

Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late-Breaking Science presentations at Heart Failure 2022, an International Congress of the European Society of Cardiology taking place online and in Madrid, Spain from May 21, 2022 May 24, 2022. The presentations will include interim data from the open-label extension study of aficamten, REDWOOD-HCM OLE (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM) and two additional analyses from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), one on the effect of treatment with omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF) and low blood pressure, and the other on the impact of tricuspid regurgitation on clinical outcomes in patients with HFrEF Continue reading →

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. AGOURA HILLS, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. Continue reading →

This article was originally published here Endocrinology. 2022 May 15:bqac072. Continue reading →

A new observational study has explored the effect of coffee consumption on serum total cholesterol (STC) levels in adult populations. The research team also collected data on how different brewing methods affect STC, discovering an association that differed across sexes. Their work is published in Open Heart Continue reading →

By James Shea Virginia Commonwealth University will recognize six faculty members for outstanding teaching, scholarship and service at the 39th annual Faculty Convocation. Continue reading →

Correspondence: Kris V Kowdley Liver Institute Northwest, 3216 NE 45th Pl, Suite 212, Seattle, WA, 98105, Tel +1 206-536-3030 Fax +1 206-524-0749 Email [emailprotected] Abstract: Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic cholestatic immune-mediated liver disease characterized by injury to intrahepatic bile ducts that may ultimately progress to cirrhosis and liver failure and result in the need for liver transplant or death without treatment. Ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) are approved therapies for PBC and are associated with a reduced risk of progression of disease, although patients may continue to experience significant symptoms of pruritus and fatigue independent of liver disease Continue reading →

Northern Californias bay area, which includes San Francisco, San Mateo, Santa Clara, Napa, and Marin County, is home to some of the most well-established biopharma companies. The atmosphere is chill, the mood relaxed unless you happen to work for one of these scientific innovators where drive and determination are required to meet the mission. Continue reading →

Representative Image Hospitalised COVID-19 patients are five times more likely to succumb to the deadly virus due to undetected signs of heart failure. The new study has highlighted that COVID-19 patients with a first-phase ejection fraction of less than 25% had a nearly five-fold higher risk of death than those with an ejection fraction of 25% or higher. Continue reading →